Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IV study of dapagliflozin in Chinese adults with chronic kidney disease
CTR20242417Phase 4Active
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Sep 2024; status: active.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20242417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242417.